Absci’s (ABSI) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research reissued their buy rating on shares of Absci (NASDAQ:ABSI) in a report released on Thursday morning,Benzinga reports. They currently have a $16.00 price objective on the stock.

ABSI has been the topic of a number of other reports. KeyCorp lifted their price target on shares of Absci from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Guggenheim reissued a “buy” rating on shares of Absci in a report on Monday, September 28th. JPMorgan Chase & Co. raised their price objective on Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Wall Street Zen upgraded Absci from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a report on Thursday, October 15th. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.00.

Absci Trading Down 9.7%

NASDAQ:ABSI opened at $9.14 on Thursday. The stock has a 50-day moving average price of $9.66 and a 200 day moving average price of $6.78. The stock has a market capitalization of $1.57 billion, a P/E ratio of -11.43 and a beta of 2.22. Absci has a 12-month low of $2.24 and a 12-month high of $12.54.

Absci (NASDAQ:ABSI) last posted its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting analysts’ consensus estimates of ($0.19). Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.66 million. On average, research analysts predict that Absci will post -0.76 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of Absci during the 2nd quarter valued at about $141,112,000. Siren L.L.C. bought a new stake in Absci during the first quarter worth approximately $5,400,000. Parkman Healthcare Partners LLC purchased a new stake in Absci during the second quarter valued at approximately $10,366,000. Bank of America Corp DE purchased a new stake in Absci during the second quarter valued at approximately $6,560,000. Finally, Artia Global Partners LP bought a new stake in shares of Absci in the 2nd quarter valued at approximately $5,383,000. 52.05% of the stock is owned by hedge funds and other institutional investors.

Recent Absci Headlines

These are some of the ABSI headlines that stood out recently:

• Positive Sentiment: Absci said its ABS-201 HEADLINE trial for pattern hair loss remains on track, with 13-week interim proof-of-concept data expected in December 2026 and full 26-week results anticipated in early 2027. Those results are a key near-term catalyst. Article: Absci Q3 2026: December hair-loss data is the only number that matters
• Positive Sentiment: The company had $173.7 million in cash, cash equivalents and marketable securities at quarter-end, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Article: Absci Reports Third-Quarter Results
• Neutral Sentiment: Absci appointed Gerry Muhle, a former executive at Galderma, Allergan and GSK, as chief commercial officer. The hire adds commercialization experience, though its impact will depend on progress in the pipeline. Article: Absci Appoints Gerry Muhle as Chief Commercial Officer

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.